Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
PV4E0yLPSaC03Dx8